Anorexia News and Research

RSS

ADA releases new position paper, 'Nutrition Intervention in the Treatment of Eating Disorders'

As one of the most complicated sets of illnesses to treat, eating disorders have mental health, as well as medical and nutritional, aspects. While treatment by a multidisciplinary health-care team is considered the best practice, there is considerable debate over how to most effectively treat eating disorders and who should be on a treatment team.

2 Aug 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

Scientists identify possible genetic variations linked to eating disorders

A substantial number of people with eating disorders, such as anorexia nervosa have a chronic course. They are severely underweight and have a high likelihood of dying from malnutrition. No treatment has been found that helps people who are chronically ill. Now, a new study sheds light on the reason that some people have poor outcome.

27 Jul 2011

More men with eating disorders than previously thought

UK National Health Service (NHS) figures showing a 66 percent rise in hospital admissions for men with eating disorders in England over the last 10 years are just the “tip of the iceberg,” a UK charity said Wednesday.

13 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Individuals with anorexia nervosa have elevated mortality rate

Individuals who have eating disorders have an elevated mortality rate, especially those with anorexia nervosa (AN), according to a meta-analysis of previous studies, reported in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Jul 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

Eating disorders and abuse may increase likelihood of pregnancy and postpartum depression

One in 10 women experience depression during pregnancy or shortly after giving birth. Although the problem has received increased attention in recent years, little is known about the causes or early-warning signs of pregnancy-related depression. In a study published in the June 2011 issue of Journal of Women's Health, researchers at the University of North Carolina at Chapel Hill School of Medicine offer new clues to help doctors identify at-risk patients and refer them to treatment early on.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Children use self-induced vomiting as weight-loss strategy: Study

Children as young as ten are making themselves vomit in order to lose weight and the problem is more common in boys than girls, according to a study of nearly 16,000 school pupils published online early, ahead of print publication, by the Journal of Clinical Nursing.

16 Jun 2011

Turning back the clock on aging stem cells to make better bone

Researchers want to turn back the clock on aging stem cells so they'll make better bone.

10 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Women with higher leptin levels have fewer symptoms of depression

Women who have higher levels of the appetite-controlling hormone leptin have fewer symptoms of depression, and this apparent inverse relationship is not related to body mass index (BMI), a new study finds.

7 Jun 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Estrogen therapy improves low bone density due to anorexia nervosa in teenage girls with the disease when given as a patch or as a low oral dose that is physiological.

6 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Anorexia News and Research

ADA releases new position paper, 'Nutrition Intervention in the Treatment of Eating Disorders'

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Scientists identify possible genetic variations linked to eating disorders

More men with eating disorders than previously thought

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Individuals with anorexia nervosa have elevated mortality rate

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Eating disorders and abuse may increase likelihood of pregnancy and postpartum depression

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Children use self-induced vomiting as weight-loss strategy: Study

Turning back the clock on aging stem cells to make better bone

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Women with higher leptin levels have fewer symptoms of depression

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News